United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Real-World Strategies to Enhance the Palatability of Coformulated Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis
Lead Author: Nicole Shuckett, RD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 2, 2022
Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 1, 2022
Reduced Plasma Concentration of the Neuroinflammation Biomarker Chitinase-3-Like Protein (CHI3L1/YKL-40) in the CENTAUR Trial
Lead Author: Robert Bowser, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 1, 2022
International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Congress on Neuromuscular Diseases (ICNMD)
Date: July 9, 2022
Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results
Lead Author: Tracey Jason, PhD, Head of Medical Affairs at Amylyx Pharmaceuticals Canada
Published: Canadian Neurological Sciences Federation (CNSF)
Date: June 26, 2022
Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results
Lead Author: Lahar Mehta, MD, Head of Global Clinical Development at Amylyx Pharmaceuticals
Published: European Network to Cure ALS (ENCALS)
Date: June 2, 2022
Effect of Sodium Phenylbutyrate/Taurursodiol on Tracheostomy/Ventilation-Free Survival and Hospitalisation in Amyotrophic Lateral Sclerosis: Long-Term Results from the CENTAUR Trial
Lead Author: Sabrina Paganoni, MD, PhD
Published: Journal of Neurology, Neurosurgery and Psychiatry
Date: May 16, 2022
Survival Analyses from the CENTAUR Trial in Amyotrophic Lateral Sclerosis: Evaluating the Impact of Treatment Crossover on Outcomes
Lead Author: Sabrina Paganoni, MD, PhD
Published: Muscle & Nerve
Date: May 4, 2022
Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis and Alzheimer's Disease: Integrated Clinical Trial Experience
Lead Author: Steven E. Arnold, MD
Published: American Academy of Neurology (AAN)
Date: April 4, 2022
Expanded Access to Sodium Phenylbutyrate/Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Learnings From an ALS Community Partnership
Lead Author: Machelle Manuel, PhD, Head of Global Medical Affairs at Amylyx Pharmaceuticals
Published: Muscular Dystrophy Association (MDA)
Date: March 13 - 16, 2022